The developing utility of zebrafish models for cognitive enhancers research

Current Neuropharmacology

Volumn 10, Issue 3, 2012, Pages 263-271

  Stewart, Adam Michael ^a   Kalueff, Allan V ^b,c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ZENEREI Institute   (United States)

Author keywords

Cognition; Cognitive enhancers; Drug screening; Neurobehavioral disorders; Neuroprotective agents; Zebrafish

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINESTERASE INHIBITOR; NEUROLEPTIC AGENT; NOOTROPIC AGENT;

ALZHEIMER DISEASE; ARTICLE; AVERSIVE BEHAVIOR; BEHAVIOR; COGNITION; COGNITIVE DEFECT; GENETICS; HUMAN; MEDICAL RESEARCH; MOTOR DYSFUNCTION; NEUROPROTECTION; NONHUMAN; SCHIZOPHRENIA; TASK PERFORMANCE; ZEBRA FISH;

EID: 84867532112     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/157015912803217323     Document Type: Article

References (166)

1. Foley, J.A., Kaschel, R., Logie R.H., Della, S. S. Dual-task performance in Alzheimer's disease, mild cognitive impairment, and normal ageing. Arch. Clin. Neuropsychol., 2011, 26(4), 340-8.
2. Elvevag, B. and Goldberg, T.E. Cognitive impairment in schizophrenia is the core of the disorder. Crit. Rev. Neurobiol., 2000, 14(1), 1-21.
3. Sasson, N., Tsuchiya, N., Hurley, R., Couture, S.M., Penn, D.L., Adolphs, R., Piven, J. Orienting to social stimuli differentiates social cognitive impairment in autism and schizophrenia. Neuropsychologia, 2007, 45(11), 2580-8.
4. Backman, L., Robins-Wahlin, T.B., Lundin, A., Ginovart, N., Farde, L. Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. Brain, 1997, 120 (Pt 12), 2207-17.
5. David, B.A., Ascher, D.B., Crespi, G.A.N., Ng, H.L., Morton, C.J., Parker, M.W., Miles, L.A. Novel Therapeutic Approaches to Treat Alzheimer's Disease and Memory Disorders, 2008, OMICS Publishing Group.
6. Malhi, G.S., Loo, C., Cahill, C.M., Lagopoulos, J., Mitchell, P., Sachdev, P. Getting physical: the management of neuropsychiatric disorders using novel physical treatments. Neuropsychiatr. Dis. Treat., 2006, 2(2), 165-79.
7. Best, J.D., and Alderton, W.K. Zebrafish: An in vivo model for the study of neurological diseases. Neuropsychiatr. Dis. Treat, 2008, 4(3): p. 567-76.
8. Cerutti, D.T., and Levin E.D. Cognitive Impairment Models Using Complementary Species, in Animal Models of Cognitive Impairment, Levin E.D and Buccafusco, J.J. Ed. 2006, Boca Raton (FL).
9. Bruce-Keller, A.J., Gupta, S., Knight, A.G., Beckett, T.L., McMullen, J. M., Davis, P.R., Murphy, M.P., Van E.L.J., St Clair, D., Keller, J.N. Cognitive impairment in humanized APPxPS1 mice is linked to Abeta(1-42) and NOX activation. Neurobiol. Dis., 2011, 44(3), 317-26.
10. Fernandez, F., Morishita, W., Zuniga, E., Nguyen, J., Blank, M., Malenka, R.C., Garner, C.C. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat. Neurosci., 2007, 10(4), 411-3.
11. Chin, J., Palop, J.J., Puoliväli, J., Massaro, C., Bien-Ly, N., Gerstein, H., Scearce-Levie, K., Masliah, E., Mucke, L. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J. Neurosci., 2005, 25(42), 9694-703.
12. Terry, R.D., Masliah, E., Salmon, D.P., Butters, N., DeTeresa, R., Hill, R., Hansen, L.A., Katzman, R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol., 1991, 30(4), 572-80.
13. Kalueff, A.V., Wheaton M., and Murphy, D.L. What's wrong with my mouse model? Advances and strategies in animal modeling of anxiety and depression. Behav. Brain Res., 2007, 179(1), 1-18.
14. Rodriguiz, R.M. and Wetsel, W.C. Assessments of Cognitive Deficits in Mutant Mice, in Animal Models of Cognitive Impairment, Levin E.D. and Buccafusco J.J., Ed, 2006: Boca Raton (FL).
15. Bussey, T.J., Holmes, A., Lyon, L., Mar, A.C., McAllister, K.A., Nithianantharajah, J., Oomen, C.A., Saksida, L.M. New translational assays for preclinical modelling of cognition in schizophrenia: the touchscreen testing method for mice and rats. Neuropharmacology, 2012, 62(3), 1191-203.
16. Levin, E.D., McClernon, F.J., and Rezvani, A.H. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl), 2006, 184(3-4), 523-39.
17. Mathur, P., and Guo, S. Use of zebrafish as a model to understand mechanisms of addiction and complex neurobehavioral phenotypes. Neurobiol. Dis., 2010, 40(1), 66-72.
18. Sison, M. and Gerlai, R. Associative learning in zebrafish (Danio rerio) in the plus maze. Behav Brain Res., 2010, 207(1), 99-104.
19. Best, J.D., Berghmans, S., Hunt J.J., Clarke S.C., Fleming, A., Goldsmith, P., Roach, A.G. Non-associative learning in larval zebrafish. Neuropsychopharmacology, 2008, 33(5), 1206-15.
20. Al-Imari, L. and Gerlai, R. Sight of conspecifics as reward in associative learning in zebrafish (Danio rerio). Behav. Brain Res., 2008, 189(1), p. 216-9.
21. Wong, K., Elegante, M., Bartels, B., Elkhayat, S., Tien, D., Roy, S., Goodspeed, J., Suciu, C, Tan, J., Grimes C., Chung, A., Rosenberg, M., Gaikwad, S., Denmark, A., Jackson, A., Kadri, F., Chung, K.M., Stewart A, Gilder, T., Beeson, E., Zapolsky, I., Wu, N., Cachat, J., Kalueff, A.V. Analyzing habituation responses to novelty in zebrafish (Danio rerio). Behav. Brain Res., 2010, 208(2), 450-7.
22. Raymond, J., Chanin, S. Stewart, A.M., Kyzar, E., Gaikwad S., Roth, A., Bruce, I., Fryar, C., Varga, D., Enriquez, J., Bagawandoss, S., Pham, M., Zapolsky, I., Green, J., Desmond, D., Hester, J., Kalueff A.V. Assessing habituation phenotypes in adult zebrafish: intra- and inter-trial habituation to novelty, in Zebrafish Protocols for Neurobehavioral Research, A.V. Kalueff and A.M. Stewart, Editors. 2012, Humana Press: New York.
23. Angelucci, M.E., Vital, M.A., Cesário, C., Zadusky, C.R., Rosalen, P.L., Da Cunha, C. The effect of caffeine in animal models of learning and memory. Eur. J. Pharmacol., 1999, 373(2-3), 135-40.
24. Maroun, M., and Akirav, I. Arousal and stress effects on consolidation and reconsolidation of recognition memory. Neuropsychopharmacology, 2008, 33(2), 394-405.
25. Mello, P.B., Benetti, F., Cammarota, M., Izquierdo, I. Effects of acute and chronic physical exercise and stress on different types of memory in rats. An Acad Bras Cienc, 2008, 80(2), 301-9.
26. Best, J.D., Berghmans, S., Hunt, J.J.F.G., Fleming, A., Goldsmith, P., Roach, A.G. Non-associative learning in larval zebrafish is mediated by the nicotinic and NMDA pathways. in British Pharmacological Society. 2007. Brighton, UK.
27. Williams, F.E., White, D. and Messer, W.S. A simple spatial alternation task for assessing memory function in zebrafish. Behav. Processes, 2002, 58(3), 125-132.
28. Yu, L., Tucci, V., Kishi, S., Zhdanova, I.V. Cognitive aging in zebrafish. PLoS One, 2006, 1, e14.
29. Kishi, S., Slack, B.E., Uchiyama, J., Zhdanova, I.V. Zebrafish as a genetic model in biological and behavioral gerontology: where development meets aging in vertebrates--a mini-review. Gerontology, 2009, 55(4), 430-41.
30. Postlethwait, J.H., Woods, I.G., Ngo-Hazelett, P., Yan, Y.L., Kelly, P.D., Chu, F., Huang, H., Hill-Force, A., Talbot, W.S. Zebrafish comparative genomics and the origins of vertebrate chromosomes. Genome Res., 2000, 10(12), 1890-902.
31. Levin, E.D. Zebrafish assessment of cognitive improvement and anxiolysis: filling the gap between in vitro and rodent models for drug development. Rev. Neurosci., 2011, 22(1), 75-84.
32. Del Bene, F. and Wyart, C. Optogenetics: A new enlightenment age for zebrafish neurobiology. Dev. Neurobiol., 2012, 72(3), 404-14.
33. Higashijima, S., Masino MA, Mandel G, Fetcho JR. Imaging neuronal activity during zebrafish behavior with a genetically encoded calcium indicator. J. Neurophysiol., 2003, 90(6), p. 3986-97.
34. Tsuruwaka, Y., Konishi, T., Miyawaki, A., Takagi, M. Real-time monitoring of dynamic intracellular Ca(2+) movement during early embryogenesis through expression of yellow cameleon. Zebrafish, 2007, 4(4), 253-60.
35. Dreosti, E., Odermatt, B., Dorostkar, M.M., Lagnado, L. A genetically encoded reporter of synaptic activity in vivo. Nat. Methods, 2009, 6(12), 883-9.
36. Knopfel, T., Diez-Garcia, J. and Akemann, W. Optical probing of neuronal circuit dynamics: genetically encoded versus classical fluorescent sensors. Trends Neurosci., 2006, 29(3), 160-6.
37. Simmich, J., Staykov, E. and Scott, E. Zebrafish as an appealing model for optogenetic studies. Prog. Brain Res., 2012, 196, 145-62.
38. Peca, J. and Feng, G. Neuroscience: When lights take the circuits out. Nature, 2011, 477(7363), 165-6.
39. Levin, E.D. and Chen, E. Nicotinic involvement in memory function in zebrafish. Neurotoxicol. Teratol., 2004, 26(6), 731-5.
40. Mathur, P., Lau, B. and Guo, S. Conditioned place preference behavior in zebrafish. Nat. Protoc., 2011, 6(3), 338-45.
41. Grossman, L., Stewart, A., Gaikwad, S., Utterback, E., Wu, N., Dileo, J., Frank, K., Hart, P., Howard, H., Kalueff AV. Effects of piracetam on behavior and memory in adult zebrafish. Brain Res. Bull, 2011.
42. Platt, D., Horn, J., Summa, J.D., Schmitt-Rüth, R., Kauntz, J., Krönert, E. On the efficacy of piracetam in geriatric patients with acute cerebral ischemia: a clinically controlled double-blind study. Arch. Gerontol. Geriatr., 1993, 16(2), 149-64.
43. Winnicka, K., Tomasiak, M. Bielawska, A. Piracetam--an old drug with novel properties? Acta Pol. Pharm., 2005, 62(5), 405-9.
44. Bhattacharya, S.K., Sen, A.P., Upadhyay, S.N., Jaiswal, A.K. Anxiolytic activity of piracetam, a nootropic agent, following subchronic administration in rodents. Indian J. Exp. Biol., 1993, 31(11), 902-7.
45. Bhattacharya, S.K., Upadhyay, S.N., Jaiswal, A.K., Sen, A.P. Latency of memory consolidation induced in mice by piracetam, a nootropic agent. Indian J. Exp. Biol., 1993, 31(11), 898-901.
46. Gaikwad, S., Stewart, A., Hart, P., Wong, K., Piet, V., Cachat, J., Kalueff, A.V. Acute stress disrupts performance of zebrafish in the cued and spatial memory tests: the utility of fish models to study stressmemory interplay. Behav. Proc., 2011, 87(2), 224-30.
47. Repantis, D., Schlattmann, P., Laisney, O., Heuser I. Modafinil and methylphenidate for neuro-enhancement in healthy individuals: A systematic review. Pharmacol. Res., 2010, 62(3), 187-206.
48. Wesensten, N.J. Effects of modafinil on cognitive performance and alertness during sleep deprivation. Curr. Pharm. Des., 2006, 12(20), 2457-71.
49. Sigurgeirsson, B., Thornorsteinsson, H., Arnardóttir, H., Jóhannesdóttir, I.T., Karlsson, K.A. Effects of modafinil on sleep-wake cycles in larval zebrafish. Zebrafish, 2011, 8(3), 133-40.
50. Firstova, I., Dolotov, O.V., Kondrakhin, A., Dubynina, E.V., Grivennikov, I.A., Kovalev, G.I. Effects of nootropic drugs on hippocampal and cortical BDNF levels in mice with different exploratory behavior efficacy]. Eksp. Klin. Farmakol., 2009, 72(6), 3-6.
51. Sansone, M., Castellano, C., Battaglia, M., Ammassari-Teule, M. Effects of oxiracetam-nicotine combinations on active and passive avoidance learning in mice. Pharmacol. Biochem. Behav., 1991, 39(1), 197-200.
52. Zhao, X., Kuryatov, A., Lindstrom, J.M., Yeh, J.Z., Narahashi, T. Nootropic drug modulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons. Mol. Pharmacol., 2001, 59(4), 674-83.
53. Eilam, D. and Golani, I. Home base behavior of rats (Rattus norvegicus) exploring a novel environment. Behav. Brain Res., 1989, 34(3), 199-211.
54. Golani, I., Benjamini, Y., and Eilam, D. Stopping behavior: constraints on exploration in rats (Rattus norvegicus). Behav. Brain Res., 1993, 53(1-2), 21-33.
55. Tchernichovski, O., Benjamini, Y. and Golani, I. Constraints and the emergence of 'free' exploratory behavior in rat ontogeny. Behaviour, 1996, 133(7/8), 519-539.
56. Stewart, A., Cachat, J., Wong, K., Wu, N., Grossman, L., Suciu, C., Goodspeed, J., Elegante, M., Bartels, B., Elkhayat, S., Tien, D., Gaikwad, S., Kadri, F., Chung, K.M., Tan, J., Denmark, A., Gilder, T., DiLeo, J., Chang, K., Utterback, E., Viviano, P., Kalueff, A.V. Phenotyping of zebrafish homebase behaviors in novelty-based tests, in Zebrafish Neurobehavioral Protocols, A.V. Kalueff and J. Cachat, Editors. 2010, Humana Press: New York.
57. Stewart, A., Cachat, J., Wong, K., Gaikwad, S., Gilder, T., DiLeo, J., Chang K, Utterback, E., Kalueff, A.V. Homebase behavior of zebrafish in novelty-based paradigms. Behav. Process, 2010, 85(2), 198-203.
58. Rosemberg, D.B., Rico, E.P., Mussulini, B.H., Piato, A.L., Calcagnotto, M.E., Bonan, C.D., Dias, R.D, Blaser R.E., Souza, D.O., de Oliveira, D.L. Differences in Spatio-Temporal Behavior of Zebrafish in the Open Tank Paradigm after a Short-Period Confinement into Dark and Bright Environments. PLoS One, 2011, 6(5), e19397.
59. Kalueff, A.V., Kyzar, E., Cachat, J., Gaikwad, S., Green, J., Roth, A., Collins, C., El-Ounsi, M., Pham, M., Davis, A., Landsman, S. Novel experimental models of hallucinogenic drug action, anxiety and depression - from fish to humans. in 17th Stress and Behavior ISBS Conference, 2012, St. Petersburg, Russia.
60. Alper, K.R., Lotsof, H.S. and Kaplan, C.D. The ibogaine medical subculture. J. Ethnopharmacol., 2008, 115(1), 9-24.
61. Alper, K.R., Stajic, M. and. Gill, J.R. Fatalities temporally associated with the ingestion of ibogaine. J. Forensic. Sci., 2012, 57(2), 398-412.
62. Schechter, M.D. and Gordon, T.L. Comparison of the behavioral effects of ibogaine from three sources: mediation of discriminative activity. Eur. J. Pharmacol., 1993, 249(1), 79-84.
63. Stewart, A.M., Gaikwad, S., Kyzar, E., Kalueff A.V. Understanding spatio-temporal strategies of adult zebrafish exploration in the open field test. Brain Res., 2012, 1451, 44-52.
64. Gerhard, G.S. Comparative aspects of zebrafish (Danio rerio) as a model for aging research. Exp. Gerontol., 2003, 38(11-12), 1333-41.
65. Zhdanova, I.V., Yu, L., Lopez-Patino, M., Shang, E., Kishi, S., Guelin, E. Aging of the circadian system in zebrafish and the effects of melatonin on sleep and cognitive performance. Brain Res. Bull., 2008, 75(2-4), 433-41.
66. Lewis, D.A. andLieberman, J.A. Catching up on schizophrenia: natural history and neurobiology. Neuron, 2000, 28(2), 325-34.
67. Lipska, B.K. and Weinberger, D.R. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology, 2000, 23(3), 223-39.
68. Arguello, P.A. andGogos, J.A. Modeling madness in mice: one piece at a time. Neuron, 2006, 52(1), 179-96.
69. Powell, S.B., Zhou, X. and Geyer, M.A. Prepulse inhibition and genetic mouse models of schizophrenia. Behav. Brain Res., 2009, 204(2)., 282-94.
70. Burgess, H.A. and Granato, M. Sensorimotor gating in larval zebrafish. J. Neurosci., 2007, 27(18), 4984-94.
71. Tek, C., Gold, J., Blaxton, T., Wilk, C., McMahon, R.P., Buchanan, R.W. Visual perceptual and working memory impairments in schizophrenia. Arch. Gen. Psychiatry, 2002, 59(2), 146-53.
72. Manns, J.R., Stark, C.E. and Squire, L.R. The visual paired-comparison task as a measure of declarative memory. Proc. Natl. Acad. Sci. U. S. A., 2000, 97(22), 12375-9.
73. Powell, K.J., Hori, S.E., Leslie, R., Andrieux, A, Schellinck, H., Thorne, M., Robertson, G.S. Cognitive impairments in the STOP null mouse model of schizophrenia. Behav. Neurosci., 2007, 121(5), 826-35.
74. Kvajo, M., McKellar, H., Arguello, P.A., Drew, L.J., Moore, H., MacDermott, A.B., Karayiorgou, M., Gogos, J.A. A mutation in mouse Disc1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition. Proc. Natl. Acad. Sci., 2008, 105(19), 7076-7081.
75. Redrobe, J.P., Bull, S. and Plath, N. Translational aspects of the novel object recognition task in rats abstinent following sub-chronic treatment with phencyclidine (PCP): effects of modafinil and relevance to cognitive deficits in schizophrenia. Front. Psychiatry, 2010, 1, 146.
76. Ogwang, S.P., Inspection of a novel object by wild and laboratory Zebrafish (Danio rerio H.) in the presence and absence of alarm substance, in Department of Biology University of Bergen: Bergen. 2008, p. 68.
77. Egan, R.J., Bergner, C.L., Hart, P.C., Cachat, J.M., Canavello, P.R., Elegante, M.F., Elkhayat, S.I., Bartels, B.K., Tien, A.K., Tien, D.H., Mohnot, S., Beeson, E., Glasgow, E., Amri, H., Zukowska, Z., Kalueff, A.V. Understanding behavioral and physiological phenotypes of stress and anxiety in zebrafish. Behav. Brain Res., 2009, 205(1), 38-44.
78. Wong, K., Elegante, M., Bartels, B., Elkhayat, S., Tien, D., Roy, S., Goodspeed, J., Suciu, C., Tan, J., Grimes C., Chung, A., Rosenberg, M., Gaikwad, S., Denmark, A., Jackson, A., Kadri, F., Chung K.M, Stewart A, Gilder, T., Beeson, E., Zapolsky, I., Wu, N., Cachat, J., Kalueff, A.V. Analyzing habituation responses to novelty in zebrafish (Danio rerio). Behav. Brain Res., 2009.
79. Rihel, J. and Schier, A.F. Behavioral screening for neuroactive drugs in zebrafish. Dev. Neurobiol., 2012, 72, 373-85.
80. Cachat, J., Canavello, P., Elegante, M., Bartels, B., Hart, P., Bergner, C., Egan, R., Duncan, A., Tien, D, Chung, A., Wong, K., Goodspeed, J, Tan, J, Grimes, C, Elkhayat, S., Suciu, C., Rosenberg, M., Chung, K.M., Kadri, F., Roy, S., Gaikwad S, Stewart, A., Zapolsky, I., Gilder, T., Mohnot, S., Beeson, E., Amri, H., Zukowska, Z., Soignier, R.D., Kalueff, A.V. Modeling withdrawal syndrome in zebrafish. Behav. Brain Res., 2010, 208(2), 371-6.
81. Bartus, R.T., Dean, R.L. 3rd, Beer, B., Lippa, A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science, 1982, 217(4558), 408-14.
82. Gallagher, M. and Colombo, P.J. Ageing: the cholinergic hypothesis of cognitive decline. Curr. Opin, Neurobiol., 1995, 5(2), 161-8.
83. Lawrence, A.D. and Sahakian, B.J.The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems. Neurochem. Res., 1998, 23(5), 787-94.
84. Sirvio, J. Strategies that support declining cholinergic neurotransmission in Alzheimer's disease patients. Gerontology, 1999, 45 Suppl 1, 3-14.
85. Rogers, S.L., Doody, R.S., Mohs, R.C, Friedhoff, L.T. Donepezil improves cognition and global function in Alzheimer disease: a 15- week, double-blind, placebo-controlled study. Donepezil Study Group. Arch. Intern. Med., 1998, 158(9), 1021-31.
86. Grutzendler, J. and Morris, J.C. Cholinesterase inhibitors for Alzheimer's disease. Drugs, 2001, 61(1), 41-52.
87. Greenberg, S.M., Tennis, M.K., Brown, L.B., Gomez-Isla, T., Hayden, D.L., Schoenfeld, D.A., Walsh, K.L., Corwin, C., Daffner, K.R., Friedman, P., Meadows, M.E., Sperling, R.A., Growdon, J.H., Donepezil therapy in clinical practice: a randomized crossover study. Arch. Neurol., 2000, 57(1), 94-9.
88. Imbimbo, B.P. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs, 2001. 15(5), p. 375-90.
89. Mohs, R.C., Doody, R.S., Morris, J.C., Ieni, J.R., Rogers, S.L., Perdomo, C.A., Pratt, R.D. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology, 2001, 57(3), 481-8.
90. Bontempi, B., Whelan, K.T., Risbrough, V.B., Lloyd, G.K., Menzaghi, F. Cognitive Enhancing Properties and Tolerability of Cholinergic Agents in Mice: A Comparative Study of Nicotine, Donepezil, and SIB-1553A, a Subtype-Selective Ligand for Nicotinic Acetylcholine Receptors. Neuropsychopharmacology, 2003, 28(7), 1235-1246.
91. Levin, E.D., Rose, J.E. and Abood, L. Effects of nicotinic dimethylaminoethyl esters on working memory performance of rats in the radial-arm maze. Pharmacol. Biochem. Behav., 1995, 51(2-3), 369-73.
92. Spinelli, S., Ballard, T., Feldon, J., Higgins, G.A., Pryce, C.R. Enhancing effects of nicotine and impairing effects of scopolamine on distinct aspects of performance in computerized attention and working memory tasks in marmoset monkeys. Neuropharmacology, 2006, 51(2), 238-50.
93. Hoyle, E., Genn, R.F., Fernandes, C., Stolerman, I.P. Impaired performance of alpha7 nicotinic receptor knockout mice in the fivechoice serial reaction time task. Psychopharmacology (Berl), 2006, 189(2), 211-23.
94. Katner, S.N., Davis, S.A., Kirsten, A.J., Taffe, M.A. Effects of nicotine and mecamylamine on cognition in rhesus monkeys. Psychopharmacology (Berl), 2004, 175(2), 225-40.
95. Freedman, R., Hall, M., Adler, L.E., Leonard, S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol. Psychiatry, 1995, 38(1), 22-33.
96. Riley, B.P., Makoff, A., Mogudi-Carter, M., Jenkins, T., Williamson, R., Collier, D., Murray, R. Haplotype transmission disequilibrium and evidence for linkage of the CHRNA7 gene region to schizophrenia in Southern African Bantu families. Am. J. Med. Genet., 2000, 96(2), 196-201.
97. Ackerman, K.M., Nakkula, R., Zirger, J.M., Beattie, C.E., Boyd, R.T. Cloning and spatiotemporal expression of zebrafish neuronal nicotinic acetylcholine receptor alpha 6 and alpha 4 subunit RNAs. Dev. Dyn., 2009, 238(4), 980-92.
98. Zirger, J.M., Beattie CE., McKay, D.B., Boyd, R.T. Cloning and expression of zebrafish neuronal nicotinic acetylcholine receptors. Gene Expr. Patterns, 2003, 3(6), 747-54.
99. Klee, E.W., Ebbert, J.O., Schneider, H., Hurt, R.D., Ekker, S.C. Zebrafish for the study of the biological effects of nicotine. Nicotine Tob Res., 2011, 13(5), 301-12.
100. Klee, E.W., Schneider, H., Clark K.J., Cousin, M.A., Ebbert, J.O., Hooten, W.M., Karpyak, V.M., Warner, D.O., Ekker, S.C. Zebrafish: a model for the study of addiction genetics. Hum. Genet., 2012, 131(6), 977-1008.
101. Aley, K.O. and Levine, J.D. Different mechanisms mediate development and expression of tolerance and dependence for peripheral mu-opioid antinociception in rat. J. Neurosci., 1997, 17(20), 8018-23.
102. Levin, E.D., Limpuangthip, J., Rachakonda, T., Peterson, M. Timing of nicotine effects on learning in zebrafish. Psychopharmacology (Berl), 2006, 184(3-4), 547-52.
103. Leiser, S.C., Bowlby, M.R., Comery, T.A., Dunlop, J. A cog in cognition: how the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits. Pharmacol. Ther., 2009. 122(3), 302-11.
104. Bencan, Z. and Levin, E.D. The role of alpha7 and alpha4beta2 nicotinic receptors in the nicotine-induced anxiolytic effect in zebrafish. Physiol Behav, 2008, 95(3), p. 408-12.
105. Alkondon, M., Pereira, E.F. and Albuquerque, E.X. alphabungarotoxin- and methyllycaconitine-sensitive nicotinic receptors mediate fast synaptic transmission in interneurons of rat hippocampal slices. Brain Res., 1998, 810(1-2), 257-63.
106. Frazier, C.J., Buhler A.V., Weiner, J.L., Dunwiddie, T.V. Synaptic potentials mediated via alpha-bungarotoxin-sensitive nicotinic acetylcholine receptors in rat hippocampal interneurons. J. Neurosci., 1998, 18(20), 8228-35.
107. Gray, R., Rajan, A.S., Radcliffe, K.A., Yakehiro, M., Dani, J.A. Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature, 1996, 383(6602), 713-6.
108. Kumari, V., Checkley, S.A. and Gray, J.A. Effect of cigarette smoking on prepulse inhibition of the acoustic startle reflex in healthy male smokers. Psychopharmacology (Berl), 1996, 128(1), 54-60.
109. Duncan, E., Madonick, S., Chakravorty, S., Parwani, A., Szilagyi, S., Efferen, T., Gonzenbach, S., Angrist B, Rotrosen, J. Effects of smoking on acoustic startle and prepulse inhibition in humans. Psychopharmacology (Berl), 2001, 156(2-3), 266-72.
110. Hutchison, K.E., Niaura, R., and Swift, R. The effects of smoking high nicotine cigarettes on prepulse inhibition, startle latency, and subjective responses. Psychopharmacology (Berl), 2000, 150(3), 244-52.
111. Acri, J.B. Nicotine modulates effects of stress on acoustic startle reflexes in rats: dependence on dose, stressor and initial reactivity. Psychopharmacology (Berl), 1994, 116(3), 255-65.
112. Curzon, P., Kim, D.J. and Decker, M.W. Effect of nicotine, lobeline, and mecamylamine on sensory gating in the rat. Pharmacol. Biochem. Behav., 1994, 49(4), 877-82.
113. Faraday, M.M., V.A. O'Donoghue, and Grunberg, N.E. Effects of nicotine and stress on startle amplitude and sensory gating depend on rat strain and sex. Pharmacol. Biochem. Behav., 1999, 62(2), 273-84.
114. Mackeprang, T., Kristiansen, K.T. and Glenthoj, B.Y. Effects of antipsychotics on prepulse inhibition of the startle response in drugnaive schizophrenic patients. Biol. Psychiatry, 2002, 52(9), 863-73.
115. Kumari, V., Soni, W., Mathew, V.M., Sharma, T. Prepulse inhibition of the startle response in men with schizophrenia: effects of age of onset of illness, symptoms, and medication. Arch. Gen. Psychiatry, 2000, 57(6), 609-14.
116. Braff, D.L., Geyer, M.A. and Swerdlow, N.R. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl), 2001,156(2-3), 234-58.
117. Gogos, A., Bogeski, M., and van den Buuse, M. Role of serotonin-1A receptors in the action of antipsychotic drugs: comparison of prepulse inhibition studies in mice and rats and relevance for human pharmacology. Behav. Pharmacol., 2008, 19(5-6), 548-61.
118. Swerdlow, N.R. and Geyer, M.A. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr. Bull, 1998, 24(2), 285-301.
119. Johansson, C., Jackson, D.M., Zhang, J., Svensson, L., Prepulse inhibition of acoustic startle, a measure of sensorimotor gating: effects of antipsychotics and other agents in rats. Pharmacol. Biochem. Behav., 1995, 52(4), 649-54.
120. Kapur, S., Zipursky, R., Jones, C., Remington, G., Houle, S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry, 2000, 157(4), 514-20.
121. Crossley, N.A., Constante, M., McGuire, P., Power, P. Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br. J. Psychiatry, 2010, 196(6), 434-9.
122. Jones, D.N.C., Gartlon, J.E., Minassian, A., Perry, W., Geyer, M. Developing new drugs for schizophrenia: from animals to the clinic, in Animal and translational models for CNS drug discovery, McArthur, R. and Borsini, F. Editors. 2008, Academic Press: London. p. 199-261.
123. Meltzer, H.Y. and Massey, B.W. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr. Opin. Pharmacol., 2011, 11(1), p. 59-67.
124. Seibt, K.J., Piato, A.L., da Luz Oliveira, R., Capiotti, K.M., Vianna, M.R., Bonan, C.D. Antipsychotic drugs reverse MK-801-induced cognitive and social interaction deficits in zebrafish (Danio rerio). Behav. Brain Res., 2011, 224(1), 135-9.
125. Sison, M. and Gerlai, R. Behavioral performance altering effects of MK-801 in zebrafish (Danio rerio). Behav. Brain Res., 2011, 220(2), 331-7.
126. Swain, H.A., Sigstad, C., and Scalzo, F.M. Effects of dizocilpine (MK- 801) on circling behavior, swimming activity, and place preference in zebrafish (Danio rerio). Neurotoxicol. Teratol., 2004, 26(6), 725-9.
127. Stewart, A., Gaikwad, S., Kyzar, E., Green, J., Roth, A., Kalueff, A.V. Modeling anxiety using adult zebrafish: a conceptual review. Neuropharmacology, 2012, 62(1), 135-43.
128. Sison, M. and Gerlai, R. Associative learning performance is impaired in zebrafish (Danio rerio) by the NMDA-R antagonist MK-801. Neurobiol. Learn. Mem., 2011, 96(2), 230-7.
129. Kim, Y.H., Lee, Y., Kim, D., Jung, M.W., Lee, C.J. Scopolamineinduced learning impairment reversed by physostigmine in zebrafish. Neurosci. Res., 2010, 67(2), 156-61.
130. Riehl, R., Kyzar, E., Allain, A., Green, J., Hook, M., Monnig, L., Rhymes, K., Roth, A., Pham, M., Razavi, R., Dileo, J., Gaikwad, S., Hart, P., Kalueff, A.V. Behavioral and physiological effects of acute ketamine exposure in adult zebrafish. Neurotoxicol. Teratol., 2011, 33(6), 658-667.
131. Carvan, M.J 3rd., Loucks, E., Weber D.N., Williams, F.E. Ethanol effects on the developing zebrafish: neurobehavior and skeletal morphogenesis. Neurotoxicol. Teratol., 2004, 26(6), 757-68.
132. Gerlai, R. High-throughput behavioral screens: the first step towards finding genes involved in vertebrate brain function using zebrafish. Molecules, 2010, 15(4), 2609-22.
133. Tomasiewicz, H.G. Flaherty, D.B., Soria, J.P., Wood, J.G. Transgenic zebrafish model of neurodegeneration. J. Neurosci. Res., 2002, 70(6), 734-45.
134. Newman, M., Musgrave I.F., and Lardelli, M. Alzheimer disease: amyloidogenesis, the presenilins and animal models. Biochim. Biophys. Acta, 2007, 1772(3), 285-97.
135. Bird, T.D. Genetic factors in Alzheimer's disease. N. Engl. J. Med., 2005, 352(9), 862-4.
136. Chen, Q., Nakajima, A., Choi, S.H., Xiong, X., Tang, Y.P. Loss of presenilin function causes Alzheimer's disease-like neurodegeneration in the mouse. J. Neurosci. Res., 2008, 86(7), 1615-25.
137. Newman, M., Verdile, G., Martins, R.N., Lardelli, M. Zebrafish as a tool in Alzheimer's disease research. Biochim. Biophys. Acta, 2011, 1812(3), 346-52.
138. Wood, J.D., Bonath, F., Kumar, S., Ross, C.A., Cunliffe, V.T. Disrupted-in-schizophrenia 1 and neuregulin 1 are required for the specification of oligodendrocytes and neurones in the zebrafish brain. Hum. Mol. Genet, 2009, 18(3), p. 391-404.
139. Hikida, T., Jaaro-Peled, H., Seshadri, S., Oishi, K., Hookway, C., Kong, S., Wu, D., Xue, R., Andradé, M., Tankou, S, Mori, S., Gallagher, M., Ishizuka, K., Pletnikov, M., Kida, S., Sawa, A. Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proc, Natl. Acad. Sci. U. S. A., 2007, 104(36), 14501-6.
140. Li, W., Zhou, Y., Jentsch, J.D., Brown, R.A., Tian, X., Ehninger, D, Hennah, W., Peltonen, L., Lönnqvist J, Huttunen, M.O., Kaprio, J., Trachtenberg, J.T., Silva, A.J., Cannon, T.D. Specific developmental disruption of disrupted-in-schizophrenia-1 function results in schizophrenia-related phenotypes in mice. Proc. Natl. Acad. Sci. U. S. A., 2007, 104(46), 18280-5.
141. Levin, E.D., Sledge, D., Roach, S., Petro, A., Donerly, S., Linney, E. Persistent behavioral impairment caused by embryonic methylphenidate exposure in zebrafish. Neurotoxicol. Teratol., 2011, 33(6), 668-73.
142. Lange, M., Norton, W., Coolen, M., Chaminade, M., Merker, S., Proft, F., Schmitt, A., Vernier, P., Lesch, K.P., Bally-Cuif, L. The ADHDsusceptibility gene lphn3.1 modulates dopaminergic neuron formation and locomotor activity during zebrafish development. Mol. Psychiatry, 2012, 17(9), 946-54.
143. Ullmann, J.F., Cowin, G., Kurniawan, N.D., Collin, S.P. A threedimensional digital atlas of the zebrafish brain. Neuroimage, 2010, 51(1), 76-82.
144. Hua, X. Leow, A.D., Lee, S., Klunder, A.D, Toga, A.W., Lepore, N., Chou, Y.Y., Brun, C., Chiang, M.C., Barysheva M., Jack, C.R Jr., Bernstein, M.A., Britson, P.J., Ward, C.P., Whitwell, J.L., Borowski, B., Fleisher, A.S., Fox, N.C., Boyes, R.G., Barnes, J., Harvey, D., Kornak, J., Schuff, N., Boreta, L., Alexander, G.E., Weiner, M.W., Thompson, P.M. 3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry. Neuroimage, 2008, 41(1), 19-34.
145. Rusinek, H., De Santi, S., Frid, D., Tsui, W.H., Tarshish, C.Y., Convit, A., de Leon, M.J. Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging. Radiology, 2003, 229(3), 691-6.
146. Beyer, M.K., Janvin, C.C., Larsen, J.P., Aarsland, D. A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. J. Neurol. Neurosurg. Psychiatry, 2007, 78(3), 254-9.
147. Melzer, T.R., Watts, R., MacAskill, M.R., Pitcher, T.L., Livingston, L., Keenan, R.J., Dalrymple-Alford, J.C., Anderson, T.J. Grey matter atrophy in cognitively impaired Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 2012, 83(2), p. 188-94.
148. Sporns, O., G. Tononi, and Kotter, R. The human connectome: A structural description of the human brain. PLoS Comput. Biol., 2005, 1(4), e42.
149. Potikanond, D. and Verbeek, F. 3D Visual Integration of Spatio- Temporal Gene Expression Patterns on Digital Atlas of Zebrafish Embryo using Web Service. in Int. Conf. on Advances in Communication and Information Technology. 2011. Amsterdam, Netherlands.
150. Axer, M., Amunts, K., Grässel, D., Palm, C., Dammers, J., Axer, H., Pietrzyk, U., Zilles, K. A novel approach to the human connectome: ultra-high resolution mapping of fiber tracts in the brain. Neuroimage, 2011, 54(2), 1091-101.
151. Bullmore, E.T. and Bassett, D.S. Brain Graphs: Graphical Models of the Human Brain Connectome. Annu. Rev. Clin. Psychol., 2011.
152. Sporns, O. The human connectome: a complex network. Ann. N. Y. Acad. Sci., 2011, 1224, 109-25.
153. T.A. Weissman, J.R. Sanes, J.W. Lichtman, J. Livet. Generation and imaging of Brainbow mice. Cold Spring Harb. Protoc., 2011(7), 851-6.
154. Livet, J. The brain in color: transgenic Brainbow mice for visualizing neuronal circuits. Med. Sci. (Paris), 2007, 23(12), 1173-6.
155. Hampel, S., Chung, P., McKellar, C.E., Hall, D., Looger, L.L., Simpson, J.H. Drosophila Brainbow: a recombinase-based fluorescence labeling technique to subdivide neural expression patterns. Nat. Methods, 2011, 8(3), 253-9.
156. Pan, Y.A., Livet, J., Sanes, J.R., Lichtman, J.W., Schier, A.F., Multicolor Brainbow imaging in zebrafish. Cold Spring Harb. Protoc., 2011, p. pdb prot5546.
157. Boyden, E.S. A history of optogenetics: the development of tools for controlling brain circuits with light. F1000 Biol. Rep., 2011, 3, 11.
158. Bernstein, J.G. and Boyden, E.S. Optogenetic tools for analyzing the neural circuits of behavior. Trends Cogn. Sci., 2011, 15(12), 592-600.
159. Mancuso, J.J., Kim, J., Lee, S., Tsuda, S., Chow, N.B., Augustine, G.J. Optogenetic probing of functional brain circuitry. Exp. Physiol., 2011, 96(1), 26-33.
160. Zeng, H. and Madisen, L. Mouse transgenic approaches in optogenetics. Prog. Brain Res., 2012, 196, 193-213.
161. Han, X. Optogenetics in the nonhuman primate. Prog. Brain Res., 2012, 196, 215-33.
162. Yizhar, O., Fenno, L.E., Prigge, M., Schneider, F., Davidson, T.J., O'Shea, D.J., Sohal, V.S., Goshen, I., Finkelstein, J., Paz, J.T., Stehfest, K., Fudim, R., Ramakrishnan, C., Huguenard, J.R., Hegemann, P, Deisseroth, K. Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature, 2011, 477(7363), 171-8.
163. Kimura, Y., Okamura, Y. and Higashijima, S. alx, a zebrafish homolog of Chx10, marks ipsilateral descending excitatory interneurons that participate in the regulation of spinal locomotor circuits. J. Neurosci., 2006, 26(21), 5684-97.
164. Yaksi, E., Judkewitz, B. and Friedrich, R.W. Topological reorganization of odor representations in the olfactory bulb. PLoS Biol., 2007, 5(7), e178.
165. Helmstaedter, M., Briggman K.L., and Denk, W. 3D structural imaging of the brain with photons and electrons. Curr. Opin. Neurobiol., 2008, 18(6), 633-41.
166. Friedrich, R.W., Jacobson, G.A. and Zhu, P. Circuit Neuroscience in Zebrafish. Curr. Biol., 2010, 20(8), R371-R381.